Will rubitin/rubicatin (Zanbiga) withdraw from clinical trials for small cell lung cancer?

Currently, lurbinectedin (Lurbinectedin) has not been completely withdrawn from clinical trials for small cell lung cancer (SCLC), although some early-stage studies have been terminated or withdrawn. In fact, research on rubitidine in the treatment of SCLC is still ongoing and important progress has been made.

According to information from the clinical trial database, rubitidine has shown different research status in multiple clinical trials of SCLC. For example, the NCT05572476 study evaluated the efficacy and safety of rubitidine in combination with Durvalumab in the treatment of recurrent extensive-stage small cell lung cancer. However, the study was withdrawn midway through, for reasons that were not publicly disclosed.

Despite this, the use of rubitidine in the treatment of SCLC has not stopped. 2025Year10Month2Day, United StatesFDA Approved for the maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with rubitidine and atezolizumab (Atezolizumab). The approval was based on data from the IMforte III phase III clinical trial, which showed that the combination arm was superior to atezolizumab monotherapy in terms of progression-free survival (PFS) and overall survival (OS).

In addition, other studies of rubitidine inSCLC are ongoing. For example, the NCT05153239 study is evaluating the efficacy and safety of rubitidine in relapsed small cell lung cancer. The continuation of these studies demonstrates that rubitidine's potential in the treatment of SCLC is still receiving widespread attention.

In general, although some early clinical trials of rubitidine in small cell lung cancer were withdrawn or terminated, its research in this field has not been completely stopped. With the development of new clinical trials and the accumulation of data, rubitidine may become one of the important drugs in the treatment of SCLC.

Reference link:https://www.drugs.com